Glioma stem cells derived from individuals with high ASCL1 expression remained more competent to undergo terminal neuronal differentiation in response to Notch inhibition compared with glioma stem cells expressing low ASCL1 (Park et al., 2017). The gene discussed is ASCL1; the disease is central nervous system cancer.